New cocktail aims to keep myeloma at bay longer

NCT ID NCT03004287

Ongoing Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether adding the drug daratumumab to a standard treatment plan helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The study involves 50 participants and uses a combination of daratumumab, carfilzomib, thalidomide, and dexamethasone. The goal is to improve progression-free survival, especially for those with high-risk disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab (Darzalex) plus carfilzomib, thalidomide, and dexamethasone
What this could lead to: If successful, this could offer a more effective treatment combination for newly diagnosed multiple myeloma, potentially extending the time patients live without their cancer worsening.
What could go wrong: This is a small, early-phase study (50 participants) and results may not apply to all patients. Adding more drugs can also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.